In early trading, shares of MiNK Therapeutics, Inc. (NASDAQ: INKT) jumped 548.51% to $50.13 after a notable case report was published in Nature’s Oncogene.
Therapeutic Potential
The study reported a complete and long-lasting remission in a patient with advanced, treatment-resistant testicular cancer following treatment with an allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797. As part of its clinical research (NCT05108623), MiNK Therapeutics revealed that the case was included in the publication “Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre-treated germ cell tumor.”
The patient had not responded to a number of therapies, including platinum-based chemotherapy, autologous stem cell transplantation, and multiple immune checkpoint inhibitors, including anti-PD-1, anti-CTLA-4, and anti-TIGIT. After a single infusion of agenT-797 with nivolumab, the patient obtained a complete clinical, radiologic, and biochemical remission and remained disease-free for almost two years.
Donor iNKT cells remained detectable for six months following treatment, and the therapy showed a satisfactory safety profile with neither cytokine release syndrome (CRS) or graft-versus-host disease (GVHD).
Growing Clinical Support for agenT-797
The remarkable remission case adds to a mounting body of evidence supporting agenT-797’s efficacy in solid tumors. MiNK Therapeutics reported Phase 2 findings in second-line (2L) gastric cancer at the 2025 AACR Immuno-Oncology meeting. These data showed early tumor reduction, tumor infiltration, and immune activation in patients who had not responded to checkpoint inhibitors before.
Notably, a number of study participants had longer survival times than 12 months, which is uncommon in situations with such advanced malignancy.
Continued Progress
A further peer-reviewed case involving a patient with metastatic gastric cancer who received a single dosage of agenT-797 with nivolumab shown a 42% tumor shrinkage and more than nine months of progression-free survival, further supporting the therapy, was also reported by Oncogene.
The therapy’s potential to improve outcomes for resistant solid tumors is further supported by the fact that MiNK Therapeutics’ current Phase 2 study in gastric cancer (NCT06251973) is still available for recruitment and that more clinical readouts are anticipated soon.
